GSK plc (LON:GSK - Get Free Report) insider Julie Brown purchased 8 shares of the company's stock in a transaction dated Monday, November 11th. The shares were acquired at an average cost of GBX 1,399 ($18.00) per share, with a total value of £111.92 ($144.02).
GSK Trading Down 2.0 %
LON:GSK opened at GBX 1,369.50 ($17.62) on Wednesday. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 123.04. The stock has a market capitalization of £55.88 billion, a price-to-earnings ratio of 1,207.08, a PEG ratio of 1.24 and a beta of 0.31. The firm has a fifty day simple moving average of GBX 1,512.80 and a two-hundred day simple moving average of GBX 1,583.74. GSK plc has a 12 month low of GBX 1,352.86 ($17.41) and a 12 month high of GBX 1,823.50 ($23.47).
GSK Dividend Announcement
The business also recently declared a dividend, which will be paid on Thursday, January 9th. Shareholders of record on Thursday, November 14th will be issued a GBX 15 ($0.19) dividend. This represents a yield of 1.03%. The ex-dividend date is Thursday, November 14th. GSK's payout ratio is 5,309.73%.
Analyst Ratings Changes
GSK has been the subject of a number of analyst reports. Berenberg Bank reissued a "buy" rating and set a GBX 1,820 ($23.42) target price on shares of GSK in a research note on Tuesday, September 10th. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and set a GBX 1,850 ($23.81) target price on shares of GSK in a research note on Tuesday, September 3rd. JPMorgan Chase & Co. reissued an "underweight" rating on shares of GSK in a research note on Monday, July 29th. Finally, Shore Capital reissued a "buy" rating on shares of GSK in a research note on Wednesday, August 28th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, GSK presently has an average rating of "Moderate Buy" and an average price target of GBX 1,842.50 ($23.71).
The Crypto That’s Making Wall Street Sweat
From Crypto 101 Media | Ad
The Crypto Wall Street Is Desperate to Hide
It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest.
Click here to discover our #1 crypto for the market right now – poised for massive growth
View Our Latest Analysis on GSK
About GSK
(
Get Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
